Investigating Cell Therapy in Multiple Myeloma: Adam Sperling, MD, PhD


The physician at the Dana-Farber Cancer Institute and instructor in medicine at Harvard Medical School discussed reasons to evaluate cellular therapy in multiple myeloma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Adam Sperling, MD, PhD, physician, Dana-Farber Cancer Institute, instructor in medicine, Harvard Medical School, about the rationale to evaluate cellular therapy in multiple myeloma.

Sperling discussed how the disease biology of multiple myeloma has demonstrated clear involvement with the immune system, and immune escape is an important feature of the malignancy. As such, immune- and cellular-based therapies have been a cornerstone of treatment in this setting, Sperling adds.

In addition, myeloma plasma cells express BCMA almost universally, Sperling says. Moreover, BCMA is not present on normal cells, making it an optimal target for therapies, Sperling concludes.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.